论文部分内容阅读
[目的]探讨血浆D-dimer及PF1+2与晚期恶性肿瘤患者静脉血栓栓塞症(VTE)的相关性。[方法]150例晚期恶性肿瘤患者随机分为2组,其中117例无VTE的患者为非栓塞组,33例发生VTE的患者为栓塞组。所有患者均在化疗前及第2、第4、第6个疗程化疗后第7d至第10d期间检测血浆中D-dimer和PF1+2的含量。[结果]随着化疗的进行患者血浆D-dimer、PF1+2呈上升趋势,且栓塞组高于非栓塞组(P<0.05);恶性肿瘤患者血浆中Ddimer和PF1+2呈显著正相关关系(r=0.53,P<0.05),而D-dimer、PF1+2与患者的年龄、性别、病程、病理分型、临床分期均无相关性(P>0.05);多因素Logistic回归分析结果显示:血浆Ddimer、PF1+2是化疗后VTE发生的独立危险因素,而接受抗凝治疗是化疗后VTE发生的保护因素。[结论]血浆D-dimer、PF1+2对晚期恶性肿瘤患者VTE的发生具有一定的诊断价值,接受化疗的晚期恶性肿瘤患者应采取适当的抗凝治疗预防VTE的发生。
[Objective] To investigate the correlation between plasma D-dimer and PF1 + 2 and venous thromboembolism (VTE) in patients with advanced malignant tumors. [Method] One hundred and fifty patients with advanced malignant tumor were randomly divided into two groups, of which 117 patients without VTE were non-embolizing group and 33 patients with VTE were embolization group. All patients were detected before chemotherapy and 2, 4, 6 courses of chemotherapy after 7d to 10d between the plasma D-dimer and PF1 + 2 levels. [Results] With the progression of chemotherapy, plasma D-dimer and PF1 + 2 showed an upward trend, and the embolization group was higher than the non-embolization group (P <0.05). There was a significant positive correlation between plasma Dlimer and PF1 + 2 in patients with malignant tumor (r = 0.53, P <0.05). There was no correlation between D-dimer, PF1 + 2 and age, gender, course of disease, pathological type and clinical stage (P> 0.05) : Plasma Ddimer, PF1 + 2 is an independent risk factor for VTE after chemotherapy, and anticoagulant therapy is a protective factor of VTE after chemotherapy. [Conclusion] The plasma D-dimer and PF1 + 2 have certain diagnostic value for the occurrence of VTE in patients with advanced malignant tumors. Patients with advanced malignant tumors undergoing chemotherapy should take appropriate anticoagulant therapy to prevent the occurrence of VTE.